Could immune therapy ease nerve pain? new trial tests IVIG for small fiber neuropathy
NCT ID NCT04153422
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a drug called IVIG (Panzyga) can help people with small fiber neuropathy, a condition causing nerve pain and damage. Researchers will give 20 adults either IVIG or a placebo for 6 months, then check nerve fiber growth in skin biopsies and pain levels. The goal is to see if IVIG can improve nerve health and reduce symptoms.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Intravenous immunoglobulin (IVIG) called Panzyga
- What this could lead to
- If it works, this could point toward a treatment for small fiber neuropathy in people with certain antibodies, potentially reducing pain and improving nerve health.
- What could go wrong
- This is a small, early-phase trial with only 20 participants, so results may not apply to everyone. IVIG is not yet approved for this condition, and side effects like allergic reactions or kidney issues are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE SMALL FIBER NEUROPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Endeavor Health
RECRUITINGGlenview, Illinois, 60026, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could spinal cord stimulation help repair nerves in small fiber neuropathy?
- Hidden nerve pain in Sjögren's: study reveals true toll on life and wallet
- Fingertip wrinkle test may spot nerve damage
- Could hidden nerve damage explain pain in kids with developmental delays?
- Gene therapy targets chronic nerve pain in new trial